1. Screening for Inflammatory Markers Identifies IL-18Rα as a Potential Link between Exenatide and Its Anti-Inflammatory Effect: New Results from the Combat-JUDO Randomized Controlled Trial.
- Author
-
Stenlid, Rasmus, Cerenius, Sara Y., Manell, Hannes, Küçükemre Aydin, Banu, Mörwald, Katharina, Gomahr, Julian, Höghammar Mitkas, Marina, Eriksson, Ida, Ciba, Iris, Geiersberger, Sabine, Thivel, David, Weghuber, Daniel, Bergsten, Peter, and Forslund, Anders
- Subjects
- *
BIOMARKERS , *RESEARCH , *SAMPLE size (Statistics) , *CHILDHOOD obesity , *INFLAMMATION , *ANTI-inflammatory agents , *TREATMENT duration , *CELL receptors , *HEALTH outcome assessment , *RANDOMIZED controlled trials , *PLACEBOS , *T-test (Statistics) , *BLIND experiment , *DESCRIPTIVE statistics , *RESEARCH funding , *STATISTICAL sampling , *VASCULAR endothelial growth factors , *DATA analysis software , *EXENATIDE , *SUBCUTANEOUS injections , *PHARMACODYNAMICS - Abstract
Introduction: Obesity is associated with chronic inflammation. Chronic inflammation has also been linked to insulin resistance and type 2 diabetes, metabolic associated fatty liver disease, and cardiovascular disease. Glucagon-like peptide-1 (GLP-1) receptor analogs (GLP-1RA) are clinically used to treat obesity, with known anti-inflammatory properties. How the GLP-1RA exenatide effects inflammation in adolescents with obesity is not fully investigated. Methods: Forty-four patients were randomized to receive weekly subcutaneous injections with either 2 mg exenatide or placebo for 6 months. Plasma samples were collected at baseline and at the end of the study, and 92 inflammatory proteins were measured. Results: Following treatment with exenatide, 15 out of the 92 proteins were decreased, and one was increased. However, after adjustment for multiple testing, only IL-18Rα was significantly lowered following treatment. Conclusions: Weekly injections with 2 mg of exenatide lowers circulating IL-18Rα in adolescents with obesity, which may be a potential link between exenatide and its anti-inflammatory effect in vivo. This contributes to exenatide's pharmaceutical potential as a treatment for obesity beyond weight control and glucose tolerance, and should be further studied mechanistically. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF